Publications by authors named "F J Brennan"

Article Synopsis
  • The study examines how the Barwon South-West Public Health Unit managed COVID-19 cases during 2020, focusing on their operational model and the impact of community transmission.
  • Between March and October 2020, 575 confirmed cases were reported in the region, with a 4.7% hospitalization rate and a 1.7% fatality rate, particularly during a major outbreak in Wave 2.
  • The local interprofessional model of care was effective in controlling outbreaks, leading to the elimination of the virus within three months and offering valuable insights for future public health strategies in Victoria.
View Article and Find Full Text PDF

Our understanding of the pathogenesis of uremic pruritus (also known as CKD-associated pruritus [CKD-aP]) remains elusive. Although multiple discrete changes in the immunochemical milieu of the skin of patients with CKD-aP have been described, a coherent theory of mechanism is absent. This article proposes a theoretical model of mechanism.

View Article and Find Full Text PDF

Robust structural remodeling and synaptic plasticity occurs within spinal autonomic circuitry after severe high-level spinal cord injury (SCI). As a result, normally innocuous visceral or somatic stimuli elicit uncontrolled activation of spinal sympathetic reflexes that contribute to systemic disease and organ-specific pathology. How hyperexcitable sympathetic circuitry forms is unknown, but local cues from neighboring glia likely help mold these maladaptive neuronal networks.

View Article and Find Full Text PDF

Administration of a new drug candidate in a first-in-human (FIH) clinical trial is a particularly challenging phase in drug development and is especially true for immunomodulators, which are a diverse and complex class of drugs with a broad range of mechanisms of action and associated safety risks. Risk is generally greater for immunostimulators, in which safety concerns are associated with acute toxicity, compared to immunosuppressors, where the risks are related to chronic effects. Current methodologies for FIH dose selection for immunostimulators are focused primarily on identifying the minimum anticipated biological effect level (MABEL), which has often resulted in sub-therapeutic doses, leading to long and costly escalation phases.

View Article and Find Full Text PDF